Topiramate: Long-term maintenance of weight loss induced by a low-calorie diet in obese subjects

被引:101
作者
Astrup, A
Caterson, I
Zelissen, P
Guy-Grand, B
Carruba, M
Levy, B
Sun, X
Fitchet, M
机构
[1] Royal Vet & Agr Univ, Dept Human Nutr & LMC, DK-1958 Copenhagen, Denmark
[2] Univ Sydney, Sch Mol & Microbial Biosci, Sydney, NSW 2006, Australia
[3] Univ Utrecht, Ctr Med, Dept Internal Med Endocrinol, Utrecht, Netherlands
[4] Univ Paris 06, Paris, France
[5] Univ Milan, Dept Preclin Sci, Milan, Italy
[6] Johnson & Johnson Pharmaceut Res & Dev LLC, Raritan, NJ USA
来源
OBESITY RESEARCH | 2004年 / 12卷 / 10期
关键词
topiramate; weight loss; diet; drug therapy; behavioral modification;
D O I
10.1038/oby.2004.206
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
ASTRUP, ARNE, IAN CATERSON, PIERRE ZELISSEN, BERNARD GUY-GRAND, MICHELE CARRUBA, BRIAN LEVY, XIANG SUN, AND MARTIN FITCHET. Topiramate: long-term maintenance of weight loss induced by a low-calorie diet in obese subjects. Obes Res. 2004; 12: 1658-1669. Objective: To examine the safety and efficacy of topiramate (TPM) for maintaining weight following a low-calorie diet. Research Methods and Procedures: Obese subjects (30 BMI < 50 kg/m(2)) 18 to 75 years old received a low-calorie diet for 8 weeks. Those who lost greater than or equal to8% of their initial weight received TPM (96 or 192 mg/d) or placebo; all were on a lifestyle modification plan. Sixty weeks of medication were planned. Sponsor ended study early to develop a new controlled-release formulation with the potential to enhance tolerability and simplify dosing in this patient population. Efficacy was analyzed in subjects who completed 44 weeks of treatment before study termination. Results: Of the 701 subjects enrolled, 80% lost greater than or equal to8% of their initial body weight and were randomized; 293 were analyzed for efficacy. Most withdrawals were due to premature termination of the study. Subjects receiving TPM lost 15.4% (96 rng/d) and 16.5% (192 mg/d) of their enrollment weight by week 44, compared with 8.9% in the placebo group (p < 0.001). Subjects on TPM continued to lose weight after the run-in, whereas those on placebo regained weight. Significantly more TPM subjects lost 5%, 10%, or 15% of their randomization weight than placebo. Most adverse events were related to the central nervous system. Discussion: During a treatment period of 44 weeks, TPM was generally well tolerated, and subjects maintained weight loss initially achieved by a low-calorie diet-and produced additional clinically significant weight loss beyond that achieved by a low-calorie diet.
引用
收藏
页码:1658 / 1669
页数:12
相关论文
共 34 条
[1]   Long-term maintenance of weight loss after a very-low-calorie diet: A randomized blinded trial of the efficacy and tolerability of sibutramine [J].
Apfelbaum, M ;
Vague, P ;
Ziegler, O ;
Hanotin, C ;
Thomas, F ;
Leutenegger, E .
AMERICAN JOURNAL OF MEDICINE, 1999, 106 (02) :179-184
[2]  
Bergström A, 2001, INT J CANCER, V91, P421, DOI 10.1002/1097-0215(200002)9999:9999&lt
[3]  
::AID-IJC1053&gt
[4]  
3.0.CO
[5]  
2-T
[6]   A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity [J].
Bray, GA ;
Hollander, P ;
Klein, S ;
Kushner, R ;
Levy, B ;
Fitchet, M ;
Perry, BH .
OBESITY RESEARCH, 2003, 11 (06) :722-733
[7]   Body mass index and the prevalence of hypertension and dyslipidemia [J].
Brown, CD ;
Higgins, M ;
Donato, KA ;
Rohde, FC ;
Garrison, R ;
Obarzanek, E ;
Ernst, ND ;
Horan, M .
OBESITY RESEARCH, 2000, 8 (09) :605-619
[8]   Body-mass index and mortality in a prospective cohort of US adults [J].
Calle, EE ;
Thun, MJ ;
Petrelli, JM ;
Rodriguez, C ;
Heath, CW .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (15) :1097-1105
[9]   Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat - A randomized controlled trial [J].
Davidson, MH ;
Hauptman, J ;
DiGirolamo, M ;
Foreyt, JP ;
Halsted, CH ;
Heber, D ;
Heimburger, DC ;
Lucas, CP ;
Robbins, DC ;
Chung, J ;
Heymsfield, SB .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (03) :235-242
[10]   Topiramate as an inhibitor of carbonic anhydrase isoenzymes [J].
Dodgson, SJ ;
Shank, RP ;
Maryanoff, BE .
EPILEPSIA, 2000, 41 :S35-S39